Advertisement
ERNA or MLAB or RMD
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ERNA’s FA Score shows that 1 FA rating(s) are green whileMLAB’s FA Score has 0 green FA rating(s), and RMD’s FA Score reflects 0 green FA rating(s).
- ERNA’s FA Score: 1 green, 4 red.
- MLAB’s FA Score: 0 green, 5 red.
- RMD’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ERNA’s TA Score shows that 3 TA indicator(s) are bullish while MLAB’s TA Score has 5 bullish TA indicator(s), and RMD’s TA Score reflects 4 bullish TA indicator(s).
- ERNA’s TA Score: 3 bullish, 4 bearish.
- MLAB’s TA Score: 5 bullish, 3 bearish.
- RMD’s TA Score: 4 bullish, 4 bearish.
Price Growth
ERNA (@Biotechnology) experienced а -1.80% price change this week, while MLAB (@Electronic Equipment/Instruments) price change was -10.74% , and RMD (@Pharmaceuticals: Other) price fluctuated -4.52% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.26%. For the same industry, the average monthly price growth was +15.05%, and the average quarterly price growth was +29.52%.
The average weekly price growth across all stocks in the @Electronic Equipment/Instruments industry was -1.08%. For the same industry, the average monthly price growth was -0.16%, and the average quarterly price growth was +23.55%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.10%. For the same industry, the average monthly price growth was +6.91%, and the average quarterly price growth was +33.60%.
Reported Earning Dates
MLAB is expected to report earnings on Nov 06, 2025.
RMD is expected to report earnings on Oct 23, 2025.
Industries' Descriptions
@Biotechnology (+0.26% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Electronic Equipment/Instruments (-1.08% weekly)This industry manufactures electronic products used in various critical and sophisticated technologies, including laser-based systems, circuit and continuity testers, electro-optical measuring instruments and high-speed precision weighing and inspection equipment. Some major companies operating in this business are Canon Inc., Keysight Technologies Inc., and Fortive Corp.
@Pharmaceuticals: Other (-2.10% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| ERNA | MLAB | RMD | |
| Capitalization | 10M | 337M | 39.4B |
| EBITDA | -31.63M | 45.3M | 1.92B |
| Gain YTD | -69.615 | -51.060 | 19.269 |
| P/E Ratio | N/A | 557.29 | 28.31 |
| Revenue | 488K | 242M | 5.15B |
| Total Cash | 4.32M | N/A | 1.21B |
| Total Debt | 593K | 181M | 852M |
ERNA | MLAB | RMD | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 51 | 70 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 27 Undervalued | 95 Overvalued | 55 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 65 | |
SMR RATING 1..100 | 100 | 91 | 36 | |
PRICE GROWTH RATING 1..100 | 97 | 92 | 49 | |
P/E GROWTH RATING 1..100 | 100 | 83 | 76 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ERNA's Valuation (27) in the Medical Specialties industry is in the same range as RMD (55) and is significantly better than the same rating for MLAB (95). This means that ERNA's stock grew similarly to RMD’s and significantly faster than MLAB’s over the last 12 months.
RMD's Profit vs Risk Rating (65) in the Medical Specialties industry is somewhat better than the same rating for ERNA (100) and is somewhat better than the same rating for MLAB (100). This means that RMD's stock grew somewhat faster than ERNA’s and somewhat faster than MLAB’s over the last 12 months.
RMD's SMR Rating (36) in the Medical Specialties industry is somewhat better than the same rating for MLAB (91) and is somewhat better than the same rating for ERNA (100). This means that RMD's stock grew somewhat faster than MLAB’s and somewhat faster than ERNA’s over the last 12 months.
RMD's Price Growth Rating (49) in the Medical Specialties industry is somewhat better than the same rating for MLAB (92) and is somewhat better than the same rating for ERNA (97). This means that RMD's stock grew somewhat faster than MLAB’s and somewhat faster than ERNA’s over the last 12 months.
RMD's P/E Growth Rating (76) in the Medical Specialties industry is in the same range as MLAB (83) and is in the same range as ERNA (100). This means that RMD's stock grew similarly to MLAB’s and similarly to ERNA’s over the last 12 months.
| ERNA | MLAB | RMD | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 76% | 2 days ago 63% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 71% | 2 days ago 71% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 68% | 2 days ago 52% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 73% | 2 days ago 66% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 75% | 2 days ago 55% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 77% | 2 days ago 52% |
| Advances ODDS (%) | N/A | 22 days ago 68% | 17 days ago 63% |
| Declines ODDS (%) | 6 days ago 90% | 7 days ago 78% | 2 days ago 57% |
| BollingerBands ODDS (%) | 2 days ago 83% | 2 days ago 60% | 2 days ago 65% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 73% | 2 days ago 65% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DIEM | 31.05 | 0.04 | +0.13% |
| Franklin Emerging Mkt Core Div TltIdxETF | |||
| QMAR | 31.57 | -0.12 | -0.36% |
| FT Vest Nasdaq-100 Buffer ETF – Mar | |||
| UTG | 37.52 | -0.42 | -1.11% |
| Reaves Utility Income Fund | |||
| AIBU | 45.96 | -0.54 | -1.16% |
| Direxion Daily AI And Big Data Bull 2X | |||
| SCO | 16.17 | -0.89 | -5.22% |
| ProShares UltraShort Bloomberg Crude Oil | |||
MLAB and
Correlation & Price change
A.I.dvisor indicates that over the last year, MLAB has been loosely correlated with NOVT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if MLAB jumps, then NOVT could also see price increases.
| Ticker / NAME | Correlation To MLAB | 1D Price Change % | ||
|---|---|---|---|---|
| MLAB | 100% | -5.23% | ||
| NOVT - MLAB | 54% Loosely correlated | -3.71% | ||
| TRMB - MLAB | 48% Loosely correlated | -2.78% | ||
| VNT - MLAB | 45% Loosely correlated | -1.19% | ||
| KEYS - MLAB | 42% Loosely correlated | +0.22% | ||
| FTV - MLAB | 42% Loosely correlated | -1.04% | ||
More | ||||
RMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, RMD has been loosely correlated with SOLV. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RMD jumps, then SOLV could also see price increases.
| Ticker / NAME | Correlation To RMD | 1D Price Change % | ||
|---|---|---|---|---|
| RMD | 100% | -1.28% | ||
| SOLV - RMD | 46% Loosely correlated | -1.74% | ||
| RVTY - RMD | 40% Loosely correlated | -2.49% | ||
| SYK - RMD | 39% Loosely correlated | -0.38% | ||
| IDXX - RMD | 39% Loosely correlated | -1.18% | ||
| MTD - RMD | 38% Loosely correlated | -1.92% | ||
More | ||||